Distinct experimental efficacy of anti-Fas/APO-1/cd95 receptor antibody in human tumors

Experimental Cell Research

Volumn 268, Issue 2, 2001, Pages 162-168

  Decaudin, Didier ^a   Beurdeley Thomas, Arnaud ^a   Nemati, Fariba ^a   Miccoli, Laurent ^a   Pouillart, Pierre ^a   Bourgeois, Yveline ^a   Gonçalves, Rui Bras ^a   Rouillard, Dany ^a   Poupon, Marie France ^a  

^a CNRS   (France)

Author keywords

Antibody; Apoptosis; Fas APO 1 CD95 receptor; Human xenografted tumors

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN; FAS RECEPTOR; MEMBRANE ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR; TUMOR CELL;

MUS MUSCULUS;

EID: 0035882028     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2001.5287     Document Type: Article

References (37)

1. Apoptosis induced by anticancer drugs
2. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily
3. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood
4. Fas and Fas ligand: A death factor and its receptor
5. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor
6. Lethal effect of the anti-Fas antibody in mice
7. Fas expression prevents cholangiocarcinoma tumor growth
8. Overexpression of Fas-ligand by neuroblastoma: A novel mechanism of tumor-cell killing
9. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit
10. + tumor cells
11. The Fas/Fas-ligand system: Implications in the antitumor response and in the activity of cytotoxic agents
12. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
13. Monoclonal antibody-mediated tumor regression by induction of apoptosis
14. Gene transfer of Fas ligand induces tumor regression in vivo
15. FADD gene therapy for malignant gliomas in vitro and in vivo
16. Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for Fas ligand
17. Fas and mutant estrogen receptor chimeric gene: A novel suicide vector for tamoxifen-inducible apoptosis
18. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate
19. A rapid simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
20. Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells
21. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells
22. Response of small-cell lung cancer xenografts to chemotherapy: Multidrug resistance and direct clinical correlates
23. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens
24. Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
25. Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors
26. Glioma immunology and immunotherapy
27. Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells
28. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis
29. CD95 ligand: Lethal weapon against malignant glioma?
30. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MX11 in human glioblastoma multiforme
31. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation
32. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice
33. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis
34. Gene therapy for acute hepatitis using CrmA gene transduction
35. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor
36. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice
37. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity